At the same time, in Vero cells engineered to overexpress TMPRSS2, with the same dosages of the drugs, E-64d could only block ~25% of the infections, whereas camostat mesylate blocked nearly ~65% of the infections, indicative again of the relative utilization of the pathways in these cell lines. The gene discussed is TMPRSS2; the disease is infection.